Two FDA decisions ahead Tradipitant (Motion Sickness) Dec 30, 2025 and Bysanti (Bipolar I & Schizophrenia) Feb 21, 2026. Back-to-back catalysts with high risk and strong upside.

Zoliflodacin could become the first oral single-dose treatment for resistant gonorrhea.

Here’s why I see strong upside for Denali with the upcoming FDA PDUFA decision for Tividenofusp alfa in Hunter syndrome (MPS II) and the potential to redefine the standard of care.

Here’s why I see big upside for Corcept with two upcoming FDA PDUFA decisions for Endogenous Cushing’s syndrome and Platinum-resistant ovarian cancer.

Omeros is approaching a pivotal FDA decision on narsoplimab for TA-TMA. Here’s why this binary event could be a major market mover.